Surgery Partners Q3 revenue falls 0.8% to $815.3 million; merger amended to $25.00 a share
Surgery Partners reported third-quarter 2026 revenue down 0.8% to $815.3 million, with a net loss attributable to the company of $21.1 million and Adjusted EBITDA of $132.7 million. The same day, it amended its pending merger agreement with HealthSpan Partners to raise the cash consideration to $25.00 per share, and it will no longer provide guidance or hold an earnings call, which matters to shareholders because the deal price and timing now drive the stock's outlook.
Key points
- Q3 2026 revenue was $815.3 million, down from $821.5 million a year earlier; same-facility revenues rose 6.0%.
- Net loss attributable to Surgery Partners was $21.1 million, or $0.16 per share, versus a loss of $22.7 million, or $0.18 per share, in Q3 2025.
- The amended HealthSpan merger sets consideration at $25.00 per share in cash, an enterprise value of up to about $6.0 billion, and is still expected to close in Q1 2027.
- The amendment adds a Ticking Fee of 10% per annum on $25.00 per share if stockholder approval is obtained but the merger has not closed by March 1, 2027.
The filing
Written by AI on Nov 9, 2026, 7:16 PM ET, from this filing only.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.